Paysign’s Patient Affordability Surge Delivers 51% Revenue Growth and Record Margins in Q1 2026
Q1 Results Show Accelerating Revenue and Margin Expansion
In the first quarter of 2026, Paysign (NASDAQ: PAYS) set itself apart by delivering standout growth: total revenue climbed 50.8% year-over-year to $28.04 million, propelled largely by the company’s push into patient affordability initiatives and steady performance in plasma-related businesses. This surge in revenue was accompanied by notable profit improvements, as gross margin rose to 65%, up from last year’s 62.9%. Operating margin jumped to 23.8%, compared to 13.4% in the first quarter of 2025, marking a significant step forward in operational efficiency.
Patient Affordability Emerges as Key Growth Engine
Paysign’s fastest-growing segment was its pharma and patient affordability arm, notching an 81.9% revenue increase to $15.68 million. Over the past 12 months, Paysign added 45 new patient affordability programs, exiting the quarter with 135 active offerings. For the plasma industry vertical, revenues increased 24.9% year-over-year to $11.75 million.
| Metric | Q1 2026 | Q1 2025 | % Change |
|---|---|---|---|
| Revenue | $28.04M | $18.60M | +50.8% |
| Pharma Revenue | $15.68M | $8.62M | +81.9% |
| Plasma Revenue | $11.75M | $9.41M | +24.9% |
| Net Income | $5.44M | $2.59M | +110.3% |
| Operating Margin | 23.8% | 13.4% | +10.4 pts |
| Adjusted EBITDA | $10.59M | $4.96M | +113.4% |
| Gross Margin | 65.0% | 62.9% | +2.1 pts |
Balance Sheet Strength Supports Growth Ambitions
Paysign finished the quarter with $20.55 million in unrestricted cash and no bank debt, emphasizing management’s focus on profitable growth and flexibility for continued investment. Restricted cash increased to $158.95 million, a 10.4% rise, reflecting higher program deposits from plasma and pharma clients as participation broadened.
| Key Balance Sheet Figures | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
| Unrestricted Cash | $20.55M | $21.07M |
| Restricted Cash | $158.95M | $143.92M |
| Accounts Receivable | $94.25M | $72.19M |
| Total Assets | $312.73M | $276.25M |
Margin Expansion Underscores Operational Leverage
Profitability metrics told a compelling story: Adjusted EBITDA margin reached 37.8%, up from 26.7% a year ago, as gross dollar load and spend volumes each grew over 26%. This reflects not only revenue growth but also an improved business mix and scale benefits from new SaaS solutions.
| Profitability Margins | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Income Margin | 19.4% | 13.9% |
| EBITDA Margin | 33.2% | 23.1% |
| Adjusted EBITDA Margin | 37.8% | 26.7% |
Full-Year Guidance Projects Continued Outperformance
Looking ahead, Paysign reaffirmed its outlook and expects 2026 revenue between $106.5 million to $110.5 million (up 30-35% year-over-year), gross margins in the 60-62% range, and net income of $13.0 million to $16.0 million. Adjusted EBITDA is forecasted between $30.0 million and $33.0 million for the full year, as the company anticipates an even split between pharma and plasma program revenue.
| 2026 Guidance | Q2 2026 | Full-Year 2026 |
|---|---|---|
| Revenue ($M) | 26.2 - 26.7 | 106.5 - 110.5 |
| Gross Margin | 60.0% - 62.0% | 60% - 62% |
| Net Income ($M) | 3.5 - 4.0 | 13.0 - 16.0 |
| Diluted EPS | 0.06 - 0.07 | 0.21 - 0.26 |
| Adj. EBITDA ($M) | 7.7 - 8.5 | 30.0 - 33.0 |
| Adj. EBITDA/Share | 0.13 - 0.14 | 0.49 - 0.53 |
Key Takeaway: Growth Is Underpinned by Recurring Pharma Expansion and Cash-Flow Strength
Paysign’s results reinforce the effectiveness of a strategy anchored in patient affordability and sustained investment in SaaS-driven program management. Leadership’s confidence is backed by impressive growth across all financial metrics, operational discipline, and a robust balance sheet with ample cash and no debt. Investors and analysts watching PAYS may want to pay special attention to how rapidly the company is growing its patient affordability programs and maintaining margin expansion—notable signals for future earnings momentum.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI